AI assistant
Sending…
Traws Pharma, Inc. — Director's Dealing 2023
Feb 9, 2023
35199_dirs_2023-02-08_157631f3-31a0-4ba4-8cf5-0f1a89abf252.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2023-02-07
Reporting Person: Fruchtman Steven M (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-02-07 | Common Stock | M | 21320 | — | Acquired | 47454 | Direct |
| 2023-02-07 | Common Stock | F | 6977 | $1.36 | Disposed | 40477 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-02-07 | Restricted Stock Units | $ | M | 21320 | Disposed | Common Stock (21320) | Direct |
Footnotes
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On February 7, 2022 the reporting person was granted 63,960 restricted stock units which vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34% on the third anniversary.
More from Traws Pharma, Inc.
Annual Report
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Proxy Solicitation & Information Statement
2026
May 29
Regulatory Filings
2026
May 27
Regulatory Filings
2026
May 26
Regulatory Filings
2026
May 22
Regulatory Filings
2026
May 15
Interim / Quarterly Report
2026
May 15
Regulatory Filings
2026
May 15
Regulatory Filings
2026
May 8